Your browser doesn't support javascript.
loading
Prostate cancer antigen 3: diagnostic outcomes in men presenting with urinary prostate cancer antigen 3 scores ≥100.
Schröder, Fritz H; Venderbos, Lionne D F; van den Bergh, Roderick C N; Hessels, Daphne; van Leenders, Geert J L H; van Leeuwen, Pim J; Wolters, Tineke; Barentsz, Jelle O; Roobol, Monique J.
Afiliación
  • Schröder FH; Department of Urology, Erasmus Medical Center, Rotterdam, the Netherlands. Electronic address: secr.schroder@erasmusmc.nl.
  • Venderbos LD; Department of Urology, Erasmus Medical Center, Rotterdam, the Netherlands.
  • van den Bergh RC; Department of Urology, Erasmus Medical Center, Rotterdam, the Netherlands.
  • Hessels D; Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands.
  • van Leenders GJ; Department of Pathology, Erasmus Medical Center, Rotterdam, the Netherlands.
  • van Leeuwen PJ; Department of Urology, Erasmus Medical Center, Rotterdam, the Netherlands.
  • Wolters T; Department of Urology, Erasmus Medical Center, Rotterdam, the Netherlands.
  • Barentsz JO; Department of Radiology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands.
  • Roobol MJ; Department of Urology, Erasmus Medical Center, Rotterdam, the Netherlands.
Urology ; 83(3): 613-6, 2014 Mar.
Article en En | MEDLINE | ID: mdl-24581524
ABSTRACT

OBJECTIVE:

To describe the results of 3 rounds of diagnostic testing and linkage to the Dutch Cancer Registry for men with an initial prostate cancer antigen 3 (PCA3) score ≥100.

METHODS:

Within an earlier reported comparative study of PCA3 vs prostate-specific antigen in a prescreened population, 90 men with a PCA3 score ≥100 were identified and underwent biopsy, 28 prostate cancers (PCs) were found, 62 men remained at risk of a diagnosis of PC. All men were offered repeat testing; 6 PCs were found in 20 men at rebiopsy. Men with at least 1 negative biopsy (n = 56) were invited to undergo magnetic resonance imaging (MRI) studies and MRI-guided biopsies if indicated. Linkage to the Dutch Cancer Registry after 2.8 years of follow-up was performed for men with negative biopsies.

RESULTS:

Of the 56 men at risk, 28 agreed to participate in further testing. They were offered MRI studies; only 7 men agreed, and in 2, suspicious lesions were found and biopsies carried out. Only 1 PC was diagnosed and classified as T1c, Gleason 3 + 3 = 6. The overall findings of 3 rounds of testing and of linkage to the cancer registry show that eventually 35 PCs were detected in 90 men with PCA3 scores ≥100 (positive predictive value 38.9%).

CONCLUSION:

Finding no PC despite extended diagnostic efforts in many men with initial PCA3 scores ≥100 is unexpected and might be clinically relevant.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Próstata / Neoplasias de la Próstata / Biomarcadores de Tumor / Antígenos de Neoplasias Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Aged / Humans / Male / Middle aged Idioma: En Revista: Urology Año: 2014 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Próstata / Neoplasias de la Próstata / Biomarcadores de Tumor / Antígenos de Neoplasias Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Aged / Humans / Male / Middle aged Idioma: En Revista: Urology Año: 2014 Tipo del documento: Article